Orca-T Improves Post-Transplant Survival in Patients With Blood Cancers
February 26th 2024Orca-T outperformed post-transplant cyclophosphamide when it came to relapse-free survival and overall survival in patients with blood cancer who underwent a stem cell transplantation from a matched unrelated donor.
Read More
Tukysa Plus Kadcyla Improves PFS in Previously Treated HER2+ Metastatic Breast Cancer
December 7th 2023The introduction of Tukysa to Kadcyla emtansine significantly improved progression-free survival versus placebo plus Kadcyla in patients with previously treated HER2-positive metastatic breast cancer.
Read More
Presurgical Keytruda Plus Chemotherapy Improves Response for Some With Breast Cancer
October 23rd 2023Neoadjuvant Keytruda plus chemotherapy followed by adjuvant Keytruda plus endocrine therapy generated a statistically significant increase in pathologic complete response compared to pre-surgical placebo and chemotherapy followed by adjuvant Keytruda and endocrine therapy for patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Read More
The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.
Read More